The SBI Healthcare Opportunities Fund has delivered an 18.9% one-year return, outperforming peers like Mirae Asset and DSP Healthcare Funds. While the fund has consistently beaten its benchmark over three years, investors should be aware that sectoral funds carry a very high risk profile due to their exclusive focus on the pharma and healthcare industry. This concentration means the fund is more vulnerable to sector-specific downturns than diversified equity portfolios.
The SBI Healthcare Opportunities Fund has emerged as a leader among sectoral mutual funds in the pharma and healthcare space. As of August 2026, the fund reported a 18.9% one-year return, placing it ahead of competitors such as the Mirae Asset Healthcare Fund, which posted a 17.9% return, and the DSP Healthcare Fund, which delivered 12.4% over the same period.
The fund’s performance is notable not just in the short term but also over a longer duration. Over a three-year period, the SBI Healthcare Opportunities Fund achieved a 23.3% compounded annual growth rate (CAGR), significantly outpacing its benchmark return of 16.8%. This sustained performance has drawn investor interest, especially as pharmaceutical companies navigate complex global supply chains and domestic pricing regulations.
However, investors looking at these returns should understand the nature of sectoral funds. Unlike diversified mutual funds that spread risk by investing across various industries like banking, IT, and manufacturing, this fund is mandated to invest at least 80% of its assets in healthcare and pharmaceutical companies. This focus is a double-edged sword. While it allows the fund to capture the upside when the pharma sector performs well, it also exposes the portfolio to high concentration risk. If the healthcare industry faces problems—such as stricter drug pricing caps, regulatory audits of manufacturing units, or a slowdown in exports—the fund has limited ability to offset these losses with gains from other sectors.
Because of this structure, sectoral funds are classified as having a very high risk profile. Market volatility in these funds can be sharper compared to diversified equity funds. The performance of this fund is heavily tied to the fortunes of its top holdings, which are typically large and mid-sized pharma companies. Consequently, investors are often advised that such funds should only form a small part of a well-balanced portfolio rather than the core holding.
Looking ahead, investors tracking this fund should monitor sector-specific developments. Key factors that could influence future returns include shifts in government healthcare policies, raw material costs for drug manufacturing, and the success of new drug approvals in international markets. It is also important to consider the cost of investing, including exit loads, which may apply if units are redeemed within a short timeframe, and the prevailing tax structure on capital gains. Investors may also want to compare these returns against broader market indices to see if the sectoral bet is generating enough value to justify the additional risk taken.